Printer Friendly
The Free Library
19,595,263 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Aquasearch and Cyanotech Settle Intellectual Property Litigation.


Business Editors and Medical/Health Writers

KAILUA-KONA, Hawaii--(BW HealthWire)--March 6, 2001

Cyanotech Corporation (Nasdaq NMS See NetWare Management System. : CYAN) and Aquasearch, Inc. (OTCBB OTCBB

See OTC Bulletin Board (OTCBB).
: AQSE.OB) today announced that they settled the intellectual property litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute.

When a person begins a civil lawsuit, the person enters into a process called litigation.
 between the two companies without admission of liability by either party. Terms of the agreement will remain confidential.

Under the agreement, Cyanotech has agreed to an injunction injunction, in law, order of a court directing a party to perform a certain act or to refrain from an act or acts. The injunction, which developed as the main remedy in equity, is used especially where money damages would not satisfy a plaintiff's claim, or to  that prevents it from using any tube system for microalgal production that infringes Aquasearch's U.S. Patent No. 5,541,056. Aquasearch has agreed that Cyanotech's current proprietary process for producing microalgae microalgae

unicellular aquatic plants (phytoplankton), the starting point of the aquatic food chain. Include toxic microalgae which are important causes of marine fish mortalities, especially Alexandrium, Chaltonella, Heterosigma spp.
, known as the PhytoDome, does not infringe in·fringe  
v. in·fringed, in·fring·ing, in·fring·es

v.tr.
1. To transgress or exceed the limits of; violate: infringe a contract; infringe a patent.

2.
 its U.S. Patent No. 5,541,056. Cyanotech will also pay undisclosed royalties to Aquasearch. Cyanotech believes that such payments will not have a material effect on Cyanotech's financial condition or results of operations.

Both Cyanotech and Aquasearch have agreed to dismiss all claims with prejudice that the parties asserted in the litigation. The Court will enter an Order to that effect and that Aquasearch's U.S. Patent No. 5,541,056 is valid and enforceable.

Aquasearch's "Safe-Harbor" Statement

This press release contains forward-looking for·ward-look·ing
adj.
Concerned with or making provision for the future: forward-looking educators; a forward-looking corporate plan.

Adj. 1.
 information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding the potential efficacy of astaxanthin in any setting as well as statements that include the words "believes," "expects," "anticipates," "intends," or similar expressions. Such forward-looking statements forward-looking statement

A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections.
 involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Aquasearch to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Aquasearch's Annual Report on Form 10-KSB for the fiscal year ended October 31, 1999 and any subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Aquasearch assumes no responsibility to update the information included herein for events occurring after the date hereof here·of  
adv.
Of this.


hereof
Adverb

Formal or law of or concerning this

Adv. 1. hereof - of or concerning this; "the twigs hereof are physic"
.

Cyanotech's "Safe-Harbor" Statement

Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, changes in sales levels to our largest customers, weather patterns, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's recent quarterly 10-Q and annual 10-K filings with the Securities and Exchange Commission.
COPYRIGHT 2001 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Mar 6, 2001
Words:420
Previous Article:Gyyr Inc. Separates Into Two Divisions.
Next Article:GVC Corporation, Taiwan, Joins the Success Story of ART's smARTspeak Technology.
Topics:



Related Articles
Cyanotech Begins Second Clinical Trial for BioAstin: Sports Nutrition Supplement for Delayed Onset Muscle Soreness.
Cyanotech Begins New Clinical Evaluation for BioAstin: Antioxidant Supplement for Sunburn Protection.
Cyanotech Receives Notice of Allowance for Carpal Tunnel Syndrome Patent.
Cyanotech Reports First Quarter Fiscal 2002 Financial Results.
Cyanotech Receives Audubon Society's Corporate Conservation Award.
Cyanotech Announces Expansion of Its Natural Astaxanthin Production; Strong Demand Is Creating Order Backlog.
Cyanotech Names Bob Capelli as Director of Sales.
Cyanotech Japan YK Formed to Service Growing Market Demand.
Cyanotech to Supply Natural Astaxanthin to Twinlab for New Consumer Products.
Cyanotech Receives Notice of Allowance for Patent Covering the Use of Astaxanthin to Retard and Prevent Sunburn.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles